This week on “The Top Line,” we’re diving into the topic of diversity in clinical trials, examining both the progress made and the ongoing work needed to ensure inclusivity. 

In this episode, Fierce Biotech Senior Editor Annalee Armstrong engages in a conversation with Karen Correa, Ph.D., Head of Global Clinical Operations at Takeda and Executive Sponsor of Trial Diversity. Correa shares her insights into why it's imperative for pharmaceutical companies to adapt and prioritize diversity in their clinical trials, while also discussing the initiatives Takeda has undertaken in this area. 

To learn more about the topics in this episode: 
Clinical trial diversity craters out to lowest level in 10 years, IQVIA finds
ASCO, ACCC become latest to call for clinical trial diversity with 6 strategies for improving inclusion in cancer studies
Digital Medicine Society rolls out initiative to improve diversity in clinical trials
FDA's Richard Pazdur, sector leaders push for private-public partnership to boost DEI in cancer drug development

This week on “The Top Line,” we’re diving into the topic of diversity in clinical trials, examining both the progress made and the ongoing work needed to ensure inclusivity. 
In this episode, Fierce Biotech Senior Editor Annalee Armstrong engages in a conversation with Karen Correa, Ph.D., Head of Global Clinical Operations at Takeda and Executive Sponsor of Trial Diversity. Correa shares her insights into why it's imperative for pharmaceutical companies to adapt and prioritize diversity in their clinical trials, while also discussing the initiatives Takeda has undertaken in this area. 
To learn more about the topics in this episode: 
<ul>
<li><a href="https://www.fiercebiotech.com/biotech/clinical-trial-diversity-craters-out-lowest-level-10-years-iqvia-finds" data-cke-saved-href="https://www.fiercebiotech.com/biotech/clinical-trial-diversity-craters-out-lowest-level-10-years-iqvia-finds">Clinical trial diversity craters out to lowest level in 10 years, IQVIA finds</a></li>
<li><a href="https://www.fiercebiotech.com/biotech/calls-clinical-trial-diversity-not-dying-down-asco-accc-issue-6-new-strategies-improving" data-cke-saved-href="https://www.fiercebiotech.com/biotech/calls-clinical-trial-diversity-not-dying-down-asco-accc-issue-6-new-strategies-improving">ASCO, ACCC become latest to call for clinical trial diversity with 6 strategies for improving inclusion in cancer studies</a></li>
<li><a href="https://www.fiercebiotech.com/cro/digital-medicine-society-rolls-out-initiative-improve-diversity-clinical-trials" data-cke-saved-href="https://www.fiercebiotech.com/cro/digital-medicine-society-rolls-out-initiative-improve-diversity-clinical-trials">Digital Medicine Society rolls out initiative to improve diversity in clinical trials</a></li>
<li><a href="https://www.fiercebiotech.com/biotech/fdas-pazdur-and-other-leaders-push-private-public-partnership-boost-dei-cancer-development" data-cke-saved-href="https://www.fiercebiotech.com/biotech/fdas-pazdur-and-other-leaders-push-private-public-partnership-boost-dei-cancer-development">FDA's Richard Pazdur, sector leaders push for private-public partnership to boost DEI in cancer drug development</a></li>
</ul>

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning. 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.&nbsp;

The Top Line

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We’ll analyze the week’s biggest business news—from mergers and marketing to drug R&D and device development. Available every Friday morning.

 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We&rsquo;ll analyze the week&rsquo;s biggest business news&mdash;from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.
&nbsp;

Advertisement